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Abstract:Chagas disease is one of the most important public health problems in Latin
America due to its high mortality and morbidity levels. There is no effective treatment for
this disease since drugs are usually toxic with low bioavailability. Serious efforts to achieve
disease control and eventual eradication have been unsuccessful to date, emphasizing the
need for rapid diagnosis, drug development, and a reliable vaccine. Novel systems for drug
and vaccine administration based on nanocarriers represent a promising avenue for Chagas
disease treatment. Nanoparticulate systems can reduce toxicity, and increase the efficacy and
bioavailability of active compounds by prolonging release, and therefore improve the
therapeutic index. Moreover, nanoparticles are able to interact with the host’s immune
system, modulating the immune response to favour the elimination of pathogenic micro-
organisms. In addition, new advances in diagnostic assays, such as nanobiosensors, are
beneficial in that they enable precise identification of the pathogen. In this review, we
provide an overview of the strategies and nanocarrier-based delivery systems for antichagasic
agents, such as liposomes, micelles, nanoemulsions, polymeric and non-polymeric nanopar-
ticles. We address recent progress, with a particular focus on the advances of nanovaccines
and nanodiagnostics, exploring new perspectives on Chagas disease treatment.
Keywords: delivery systems, nanobiosensors, nanodiagnostics, nanoparticle systems,
nanovaccine
Introduction
Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin
America, where between five and eight million people are infected. The disease is
spreading to non-endemic countries, such as Australia, Canada, Japan, Spain and
United States of America (USA).1 It is mainly transmitted by faecal contamination
of Reduviidae insects through insect bites or another injury of the skin2 parasite can
also be spread by blood transfusion, organ transplantation, congenital contamina-
tion, and consumption of contaminated food and drinks.3 The T. cruzi biological
cycle is comprised of three fundamental forms: (1) infective trypomastigotes found
in mammalian blood and in the hindgut of triatomine bugs as metacyclic forms, (2)
epimastigotes, the proliferative form located in the bug’s midgut, and (3) amasti-
gotes that multiply by binary fission inside mammalian host cells, causing disrup-
tion and the release of new trypomastigotes into the bloodstream capable of
invading any nucleated cell to begin a new reproductive cycle.4 Regarding clinical
symptoms, Chagas disease can manifest both an acute phase which is asymptomatic
in most cases and a chronic phase that is depicted by digestive and/or cardiac
lesions.5 Treatment is based on the nitroheterocyclic compounds benznidazole and
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nifurtimox. However, in long-term therapy, both of the
aforementioned induce serious side effects and cross-resis-
tance. To date, research into the production of Chagas
disease vaccines has been conducted. The main difficulties
have been finding a protective antigen and generating
attenuated parasites that will not trigger pathology in the
long-term.6 Therefore, in the absence of vaccines, control
measures for Chagas disease remain limited to diagnosis
and treatment.5
Nanocarriers has demonstrated important results in
terms of increasing the efficacy and decreasing the toxicity
of drugs, antigens, and adjuvants currently used against
some diseases. The use of nanocarriers against pathogens
provides a greater ability to overcome biological barriers,
maintenance of drug integrity in biological media, with
higher specificity to target cells and tissues together with
prolonged drug release in comparison to conventional
drugs.7 Moreover, nanodiagnostic systems have been
developed to improve the accuracy of sample preparation
and detection of infectious pathogens by means of a sim-
ple, quick, accurate and inexpensive technique.8
In this review, we provide an overview of synthetic
methods, physical characteristics and delivery systems
based on nanocarriers for various antitrypanosomal agents,
through liposomes, micelles, mesoporous silica nanoparti-
cles, polymeric and non-polymeric nanoparticles (Figure 1).
In this context, we highlight new perspectives and innovative
strategies on the treatment of Chagas disease, as well as a
general overview of nanovaccines and nanodiagnostics.
General aspects
Physical characteristics of the nanocarriers
Some physical characteristics can influence nanocarrier
functions and thus can be strategically explored to control
the Chagas disease, especially against intracellular para-
sites, which are the most difficult forms to eliminate.
These main characteristics are: 1) size of the particles:
this feature improves greater bioavailability and circula-
tion time (release, aggregation and transport of the drug),
ranging from 1 to 100 nm or micrometric size (μm).9–11 2)
Solubility: nanostructures can encapsulate insoluble or
poorly soluble drugs, and the use of them can eliminate
the need for toxic organic solvents.12 3) Shape: it can
influence interactivity, cellular uptake, retention, biocom-
patibility, transport and drug loading capacity. The main
shapes are spheres, discs, hemispheres, cylinders, cones,
and tubes.10,11 4) Surface area: provides more reactivity as
the particle size decreases in comparison to larger mole-
cules (bulk solids), in addition, they are responsible for the
improved water solubility and bioavailability.10 5) Net
charge: it can influence the retention in the tissue, the
circulation half-life and the uptake. In fact, cationic parti-
cles can have better uptake in the electrostatic interaction
with the membrane,13,14 compared to particles with nega-
tive charges that have longer circulation half-life.15
The interactions of nanoparticles with their biological
environment (molecules, cells, organs) depend on a com-
plex interaction between controllable particle properties
and largely uncontrollable properties of the surrounding
media. Particle size, surface charge, polydispersity index,
shape, and surface chemistry are key factors that deter-
mine the performance criteria, including the degree of
protein adsorption, cell absorption, biodistribution patterns
and mechanisms.16 Regarding Chagas disease, these nano-
materials must show a high volume of distribution and
longer circulation time in the body compared to the avail-
able drugs (Nifurtimox or Benznidazole). It has been
shown that highly cationic nanoparticles are eliminated
from the circulation more rapidly than highly anionic
nanoparticles.17 In contrast, neutral nanoparticles, as well
as those with a slight negative charge, show significantly
longer circulating half-lives, since the negative nature of
cell membranes allows them to be highly absorbed by
cells.18–22 Similarly, the size of the nanoparticle, with an
average of less than 200 nm, enables a longer lifetime in
Figure 1 Nanomaterials used against Chagas disease. Strategies and application of
nanocarrier-based drug delivery systems, such as liposomes, micelles, mesoporous
silica nanoparticles, polymeric and non-polymeric nanoparticles to optimize the
delivery of antitrypanosomal agents.
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the bloodstream, by avoiding interactions with the mono-
nuclear phagocyte system and controlling drug delivery.23
Polymeric nanoparticles
Polymeric nanoparticles are solid colloidal particles
used as adjuvants in vaccines or in therapeutic agent
delivery systems that can be dissolved, entrapped,
encapsulated or adsorbed onto the constituent polymer
matrix. They are formed from natural or synthetic poly-
mers such as: poly(lactide-co-glycolide) (PLGA); poly-
lactide (PLA); polyglycolide (PGA); polycaprolactone
(PCL); poly(D, L-lactide); chitosan, and PLGA-poly-
ethylene glycol (PEG).24 Considering their biodegrad-
ability and biocompatibility, these polymers are among
the few synthetic polymers approved by the U. S. Food
and Drug Administration (FDA).25,26 Over the last
20 years, a variety of experimental administration sys-
tems with polymeric nanoparticles have been developed.
An extensive compilation of detailed information about
nanomaterials is presented in Table 1.
The first studies with polymeric nanoparticles against
Chagas disease were developed by Gonzalez-Martin et al27
and involved preparation of poly(alkyl cyanoacrylate)
nanoparticles (PACA) containing nifurtimox. PACAs are
generally formed from longer alkyl chains so degradation
is slower and less cytotoxic.28 They obtained nanoparticles
smaller than 200 nm, with 33.4% absorption to nifurtimox
and a 65.4% drug release rate, after 6 hrs of incubation at
pH 7.4. In vitro assays using nifurtimox-loaded nanopar-
ticles and parasites isolated from chronic patients (from
Northern Chile) showed the anti-epimastigote activity of
98.9% at a concentration of 0.2 μg/mL, while the same
concentration of free nifurtimox in standard solution was
approximately 40%. In addition, trypanocidal activity
showed an IC50 of 0.683 (±0.269) μg/mL for the nifurti-
mox standard solution and 0.0015±0.0006 μg/mL for
nifurtimox-loaded nanoparticles. Furthermore, electron
microscopy studies revealed that intracellular parasites
underwent a series of degenerative processes with an
accumulation of electrodense nuclear chromatin, parasite
cytoplasm autolysis, kinetoplast degeneration, and parasite
membrane lysis. Finally, cell cultures previously infected
with metacyclic parasites showed that after only 2 h of
treatment with 0.001% nifurtimox-loaded nanoparticle
suspension, parasitism was reduced by 87–94%. The
degenerative processes observed by electron microscopy
in the treated free amastigote and intracellular parasites
were not observed in the host cells.
Gonzalez-Martin et al29 synthesized the same allopur-
inol-loaded polyether cyclic nanoparticles and showed that
the pyrazolopyrimidine allopurinol has significant activity
against T. cruzi, with less toxicity than nifurtimox. The
maximum amount of allopurinol trapped in the nanoparti-
cles was 62 (±1.9) μg/mg. Furthermore, their analysis of
pH effects showed that after 6 h of incubation at pH 7.4,
the release of allopurinol was 7.4%, whereas only 3.1%
were released after 4–6 h at pH 1.2. Results of in vitro
anti-T. cruzi activity experiments (epimastigotes) were
considerably superior for allopurinol-loaded nanoparticles
compared to an allopurinol standard solution (91.5% ver-
sus 45.9%) with 16.7 μg/mL of allopurinol. Cytotoxicity
tests in Vero cells with allopurinol-loaded nanoparticles
showed an IC50 80-fold lower than the value obtained for
the free drug. The allopurinol-loaded nanoparticles signif-
icantly increased trypanocidal activity, thus these nanoma-
terials could prove to be an effective drug carrier against
T. cruzi.
In 2001, Molina et al30 used sterols in polyethylene
glycol-polylactide (PEG-PLA) nanospheres produced by
the simple emulsification method with polymerization.
Among nanoparticle characteristics, they showed a mono-
disperse size distribution of between 100 and 200 nm, and
the drug encapsulation efficiency was 90, 87 and 92% for
bis-triazole D0870, itraconazole and ketoconazole, respec-
tively. In vivo assays were performed with Swiss albino
mice infected intraperitoneally with CL or Y strains.
Treatment over 30 consecutive days with D0870-loaded
nanospheres, intravenous injection (IV), showed that the
significant cure rate reached 60 and 90% for 1.5 and 3 mg/
kg/day, respectively for both strains, whereas discharged
nanoparticles demonstrated no trypanocidal activity.
Finally, no induced healing or anti-T. cruzi activity was
observed for ketoconazole or itraconazole, not even in the
encapsulated form.
It has been well documented that endogenous nitric oxide
(NO) plays a key role in the immune system against several
intracellular pathogens.31 After infection, activated macro-
phages and other immune cells such as dendritic cells, crucial
to connecting the innate and adaptive immune responses
against T. cruzi,32 inhibit pathogen replication by releasing
several effector molecules, including NO.33,34 As a free
radical, NO is unstable and can be easily inactivated in the
biological system. In order to increase the NO half-life,
several authors described the preparation of low molecular
weight S-nitrosothiols (RSNO), an important class of NO
donors.35 However, RSNOs are thermally unstable in
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aqueous solutions and lead to the release of free NO.34 In this
context, Seabra et al36 prepared and evaluated antiparasitic
activity by incorporating biocompatible and biodegradable
polymer nanoparticles to promote sustained NO release. An
ionotropic gelation method was used to prepare chitosan/
tripolyphosphate (TPP) containing S-nitroso-mercaptosucci-
nic acid (S-nitroso-MSA), a RSNO, which acts as a sponta-
neous NO donor. The antitrypanosomal activity showed
great inhibitory effects against Y strain epimastigotes. A
dose-dependent antitrypanosomal effect was observed in
trypomastigotes with an IC50 value of 252 μg/mL and an
EC50 of 91 μg/mL, suggesting the inhibitory effect is due to
the presence of S-nitroso-MSA in the chitosan nanoparticles
since the MSA nanoparticles and sodium nitrite were non-
toxic. The S-NO groups act as a spontaneous NO donor due
to the homolytic division of S-N with the release of free NO.
The results obtained from murine peritoneal macrophage
showed an antitrypanosomal activity of 200 μg/mL with
NO-releasing nanoparticles decreasing the number of intra-
cellular amastigotes. Furthermore, the treatment conditions
tested during and after-infection indicated that NO release
can interfere with adhesion, invasion and/or T. cruzi replica-
tion in mammalian cells. The authors claimed that this toxic
effect against different T. cruzi lifecycle forms makes NO
donor S-nitroso-MSA encapsulation an interesting approach
for combating and preventing Chagas disease.
Another method of drug administration is the self-emul-
sifying drug delivery system (SEDDS) that contains a mix-
ture of drug, oil, surfactant and occasionally solvent.37 The
purpose of SEDDS is to improve drugs that have poor
hydro-solubility and ultimately increase their oral
absorption.38 Ravuconazole (RAV), an antifungal triazole
drug with potent anti-T. cruzi activity (epimastigote and
amastigote) was formulated by SEDDS with isotropic mix-
tures of anhydrous oil and surfactant.39 In vitro tests demon-
strated more than 70% anti-amastigote activity,
approximately 1.8 times more in comparison with free
RAV with an equivalent IC50 dose (0.1 nM). In addition,
in vivo toxicity tests using Swiss mice, treated with RAV-
SEDDS (10%, v/v) for 20 days, showed no weight loss for
animals treated with RAV-SEDDS or free RAV, indicating
no additional drug toxicity. The authors concluded that RAV
in the SEDDS dosage form is a strategy that merits further
in vivo experiments and preclinical studies as a potential
treatment of human T. cruzi infections.
Lychnopholide (LYC) is a bioactive compound found
in plants from the Asteraceae family that has been shown
to be a potent trypanocidal agent, but its use is limited by
its low aqueous solubility and high lipophilicity.
Therefore, Branquinho et al40 developed LYC-loaded
nanocapsules (NC) using poly-ɛ-caprolactone (PCL) and
poly (lactic acid) polyethylene glycol (PLA-PEG) poly-
mers that were subsequently tested in Swiss mice infected
intraperitoneally with T. cruzi. The mice infected with CL
or Y strain were treated with 10 and 20 doses, respectively,
of free drug LYC, Benznidazole (BNZ), LYC-PCL-NC or
LYC-PLA-PEG-NC (2 mg/kg/day). The animals infected
with the Y strain treated with LYC-PLA-PEG-NC in the
prepatent period (with treatment initiated on day 7 after
infection) for 20 days achieved 100% cure, while those
treated with BNZ and LYC-PCL-NC achieved less than
75% and 62.5% cure, respectively. This study indicated
that LYC-PLA-PEG-NC efficacy was attributed to the NCs
ability to maintain LYC release for longer periods in
biological media and when a higher number of trypomas-
tigotes in the blood were exposed to the drug.
Furthermore, PLA-PEG simultaneously performed a sus-
tained and passive directed-delivery.
Abriata et al41 developed ursolic acid-loaded nanopar-
ticles with poly-Ɛ-caprolactone (PN-UA) as a potential
option for Chagas disease treatment, however, it was
found to have low bioavailability. The PN-UA formulation
had a size of 173.2 nm (±7.28), a polydispersity of 0.09
(±0.03) and a zeta potential of −36 mV (±3.34), which are
important for particle stability, together with a maximum
efficiency of encapsulation equivalent to 94.1% (±1.31).
Cytotoxicity studies with fibroblast cells (LLC-MK2)
showed no toxicity with PN-UA (120 μM) both in 24 hrs
and 48 hrs of incubation whereas showed a 50.00±2.90%
inhibition against trypomastigotes (Y- strain) at the same
concentration. It was observed that PN-UA reduced para-
sitemia in male C57BL/6 mice, up to 3.5 times more in
comparison with benznidazole. Thus, these nanomaterials
may contribute to future clinical trials to treat Chagas
disease.
Rial et al42 evaluated C3H/HeN mice infected with T.
cruzi in the acute phase using the Nicaragua (TcN) strain
by administering benznidazole nanoparticles (BNZ-nps)
orally with 10, 25 or 50 mg/kg/day. Mice treated with
these nanoparticles survived until euthanasia (92 days
after infection, dpi). Histological analysis of cardiac tissue
showed a significant decrease in inflammation, with lower
levels of T. cruzi-specific antibodies. Additionally, Vero
cells treated with BNZ-nps led to a significant increase
in ROS production, suggesting these BNZ-nps could
reduce the administration frequency while providing a
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significant increase in the pharmacological action related
to the greater solubility together with a reduction in the
number undesirable effects associated with BNZ.
A recent study developed by Tessarolo et al43 designed
calcium carbonate nanoparticles loaded with benznidazole
(BNZ@CaCO3). The @CaCO3 nanoparticles are biode-
gradable, biocompatible and have low toxicity in
LLCMK2 cells.44 BNZ@CaCO3 was not only able to
reduce epimastigote, trypomastigote and amastigote (Y-
strain) viability showing that the amount of BNZ was up
to 25 times lower when loaded with CaCO3 nanoparticles,
they also had an improved selectivity index (SI =2.38).
Seremeta et al45 formulated nano- and multiparticulate
benznidazole polymers, by means of nanoprecipitation/
lyophilization based on Acrylates/Ammonium
Methacrylate Copolymer, aiming to increase the dissolu-
tion rate of the drug. The obtained nanoparticles had a size
range of 200–300 nm, yield of 86%, encapsulation effi-
ciency of 78%, while the load capacity was 24% p/p and a
zeta potential of 35.4±1.7 that was able to maintain during
the lyophilization process. In addition, in vitro drug release
assay showed that the nanoparticles had a higher rate
compared to free drugs. Therefore, these nanocarriers
would help in the pediatric treatments for Chagas disease,
and the powder formulation would allow the dose flex-
ibility to adapt to the dosage requirements depending on
age groups.
Liposomes
Liposomes are vesicular nanomaterials formed by a lipid
bilayer composed of phospholipids and cholesterol mole-
cules, characterized by extended, two-dimensional and
clearly separated hydrophilic and hydrophobic regions.46
These systems can deliver molecules such as ribosomes,
proteins and/or peptides, DNA, immunological adjuvants
or drugs while providing greater therapeutic efficacy with
reduced toxicity and biocompatibility in biological
systems.47–49 Over the last three decades, a variety of
experimental lipid administration systems have been
developed (Table 1).
Morilla et al50 showed that multilamellar liposome
vesicles (MLV) loaded with benznidazole (BNZ) pre-
sented three times higher accumulation in the mice
liver, in addition to 30% lower blood BNZ concentra-
tions (1.1 g/mL), compared to free BNZ treatment.
However, increased hepatic uptake of BNZ under the
conditions tested had no effect on parasitemia levels in
T. cruzi pantropic/reticulotropic RA strain-infected
mice. This strain is generally more studied in mice,
because they show high virulence and develop an early
peak of parasitaemia during acute infection. In addi-
tion, they can induce a transient deterioration of the
microbicidal activity of macrophages and the lympho-
proliferative response induced by mitogens in vitro.51
Hydrogenated trypanocidal etanidazole (ETZ) is a
drug with trypanocidal activity, but its hydrophilic struc-
ture causes slow diffusion through the membrane. In
this context, in 2005, Morilla et al52 used pH-sensitive
liposomes to encapsulate ETZ (L-ETZ). Murine macro-
phage-like cell line J774 treated with L-ETZ showed an
anti-amastigote activity of 72% (RA strain), while the
same dose of free ETZ produced no activity. In vivo
experiments in female BALB/c mice, showed a signifi-
cant decrease in parasitemia levels. In contrast, inocula-
tion of a 180-fold higher dose of free ETZ failed to
reduce the number of trypomastigotes in the blood-
stream and failed to achieve complete parasitological
cure with L-ETZ treatment. The limitations of L-ETZ
can be attributed to the fact that this nanomaterial is not
directed to several cells such as hepatic macrophages,
spleen cells, nerve cells, muscle, considering that these
liposomes are pH-sensitive. In conclusion, this study
should be conducted with charge modifications made
to the surface of this nanomaterial in order for it to
assist immune system evasion and have a greater pene-
tration capacity in most cells.
Amphotericin B (AmB) is a macrolide polyene che-
motherapy that exists in three different aggregation states:
monomer, dimer, and poly-aggregate.53 Formulations of par-
enteral AmB, either as the original micelle formulation with
sodium deoxycholate (Fungizone®) or the less nephrotoxic
and hemolytic liposomal formulation (AmBisome®), have
been used as effective treatments for visceral leishmaniasis
(VL).54 However, although AmB trypanocidal activity in
infections was reported for the first time in 1962 by Actor
et al,55 and there are several tests illustrating in vitro nano-
molar trypanocidal activity for amphotericin B-deoxycholate
and lipid formulations of AmB (amphotericin B colloidal
dispersion (Amphocil®) and hemolytic liposomal
formulation),56 only relatively few reports described the in
vivo effects of AmB liposomes in mice infected with T.
cruzi,57 with no AmB formulation authorized in the market.
However, when used against T. cruzi, high parenteral doses
(>25 mg/kg) of AmB were required for a prolonged period.
AmB has both low solubility and permeability in the gastro-
intestinal epithelium, resulting in a low oral bioavailability
Dovepress Quijia Quezada et al
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(<0.9%).58 In this context, studies carried out by Cencig et
al59 using amphotericin B liposomes showed efficacy in
BALB/cJ mice infected with Tulahuen strain trypomasti-
gotes during acute and/or chronic stages. Amphotericin B
liposomes administration by 6 intraperitoneal injections at a
dose of 25 mg/kg, at different times, showed that it prevented
the mice from having fatal problems in the acute phase. In
addition, parasitemia was reduced in acute and undetectable
phase in chronic infection. Quantitative PCR analyses
showed a significant reduction in parasite load in the heart,
liver, spleen, skeletal muscle and adipose tissues in the acute
and chronic phases. This study indicated that amphotericin B
liposomes does not completely cure T. cruzi infected mice, it
merely prevents mortality and significantly reduces parasite
load in most tissues.
Ideally, nanoparticulate systems must be efficient in
both acute stage and in the more challenging chronic
stage of the disease that is characterized by the presence
of intracellular amastigotes in different parts of the organ-
ism such as cardiac, skeletal, smooth muscle and glial
cells.60 Therefore, nanoparticulate systems must have
broad and selective targeting to infected cells (intracellular
sites of amastigotes), reducing parasite viability. The use
of pH-sensitive particles, which allow the drug release in
the cytoplasm and nests of amastigotes, has been explored,
however, reaching cellular internalization and endosomal
escape is a considerable barrier. The endosomal compart-
mentation of internalized nanoparticles, subjected to a low
pH environment and enzymes, is unfavourable to drug
loading, especially for encapsulated drugs.61
Consequently, these nanomaterials must function at differ-
ent pH levels to obtain a more drastic reduction in para-
sitemia levels, but so far, few studies relating to these
particles have been published (Figure 2).
Other types of nanomaterials
A variety of experimental administration systems have
been developed with other types of nanomaterials such
as solid lipid nanoparticles, metal nanoparticles, micelle
and nanoemulsions (Table 2).
Solid lipid nanoparticles
Solid lipid nanoparticles (SLN) are nanoparticles composed
of a solid and a liquid lipid mixture in which the lipid matrix
is solid at room and body temperature. They are stable and
have the ability to encapsulate drugs with controlled-
release. In addition, SLN has good biocompatibility,
biodegradability, high bioavailability, and also the possibi-
lity of large-scale production.62–65
5-Hydroxy-3-methyl-5-phenyl-pyrazoline-1- (S-benzyl
dithiocarbazate) (H2bdtc) belongs to the class of S-dithio-
carbazates. Previous studies have shown the effectiveness
of H2bdtc against Chagas disease, but their interference in
subsequent studies are due to its low solubility.66 In this
context, Carneiro et al67 synthesized H2bdtc-loaded with
SLN. The authors showed that H2bdtc-SLN had an effec-
tive parasitemia reduction at concentrations 100 times
lower than those normally used for benznidazole (clini-
cally applied at 400 µM/kg/day). In addition, it decreased
inflammation and damage to the liver and heart resulted in
100% survival of mice infected with the T. cruzi Y strain.
Finally, H2bdtc-SLN overcame problems inherent to the
low water solubility of the compound and it could be more
accessible to the parasite.
Immunostimulant complexes (ISCOM),68 are lipids
composed of Quillaja saponaria in a pentagonal dodeca-
hedral shape of uniform size (40 nm) used as adjuvants for
vaccines,69 such as DNA vaccines, antigen carriers for
systemic, oral and intranasal administration.70,71 The
basis of ISCOM structure is the interaction between sapo-
nin molecules, cholesterol, phospholipids and hydrophilic
and hydrophobic antigens associated in a single nanoma-
terial. When combined, they form stable rings in aqueous
solutions. These particles trigger a balanced Th1 and Th2
response and stimulate a cytotoxic cellular response that is
rarely obtained with other adjuvants.72 Encapsulation of
actinomycin D in ISCOM functionalized with antibodies
Figure 2 Hypothetical mechanisms of the internalization of pH-sensitive liposomes.
Quijia Quezada et al Dovepress
submit your manuscript | www.dovepress.com
DovePress














































































































































































































































































































































































































































































































































































































































































































































































































































































































Dovepress Quijia Quezada et al
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
DovePress
6415
produced dose-dependent effects,73 and 100% effective-
ness at 25.47×10–2 ng/mL or 196.8 times less than the
antibiotic alone, which kills the parasite within 24 h at
50 ng/mL. ISCOM functionalized with compounds con-
taining vinyl sulfone and a hydrophobic chain are capable
of binding proteins or ligands and are suitable for delivery
systems in directional therapy in which antibodies or spe-
cific ligands are required to drive them to their target.
Thus, this system increases drug effectiveness while dras-
tically reducing dosage and toxicity, which is often dis-
advantage in conventional therapy.
Mesoporous silica nanoparticles
A recent study developed by Nhavene et al74 combined
mesoporous silica nanoparticles, solid inorganic material
and chitosan coating, and effectively showed the anchor-
ing of benzonidazol molecules. These silica nanoparticles
have a network of ordered pores and uniform sizes that
help to functionalize the antichagasic agent and other
components. In transmission electron microscopy, these
nanoparticles showed a uniform shape and sizes over
3.3 nm, and zeta potential of −11.5±0.5 mV. In vitro assays
showed that these particles were thirty times more active
against CL-Brener epimastigotes than free BZ, revealing
their potential as nanoplatforms for drug delivery.
Metallic nanoparticles
Metallic nanoparticles (MNPs) are clusters of metal
atoms with optoelectronic and physicochemical proper-
ties that are strongly dependent on their size, shape,
crystallinity, and structure. MNPs are used for a wide
range of applications such as molecular diagnostics,
electronics, catalysis, together with the delivery of
drugs, antibodies, and other ligands. However, potential
toxicity and other properties that might influence toxic
responses must also be studied and understood. A study
conducted by Eger and Soares (2012),75 monitored
intracellular endocytosis in epimastigotes (strain
Dm28c) with gold nanoparticles marked with transferrin
(iron-specific transport protein in the plasma of humans
and mammals) by confocal microscopy (633nm) and
evidenced two sites of parasite that represent the lower
part of the cytopharynx and reservosomes, being able to
visualize the basic aspects of endocytosis. This study
opens up promising routes for immunolocalization
research with secondary antibodies labeled with Au.
Quantum dots
Quantum dots (QD) have unique autofluorescence proper-
ties and thus have great potential in biomedicine for diag-
nosis, drug delivery and imaging.76 These nanoparticles
can have adverse effects in vitro and in vivo and pose
potential risks to human health. QDs can be distributed to
all body systems and they can be added in some tissues
and organs.77,78 QDs deposited in cells can alter cell
viability and morphology, including induction of chroma-
tin condensation and apoptosis.79,80
In 2010, Stahl et al81 evaluated the possible effects of
quantum dots of cadmium telluride (CdTe) in T. cruzi epi-
mastigotes (clone Dm28). Using high doses of QD (20 and
200 μM) led to a decrease in T. cruzi growth patterns.
Additionally, the concentrations used to label T. cruzi and
intestinal epithelial cells from Rhodnius prolixus were 2 and
10 μM of CdTe and CdSe, respectively, encouraging further
study into the interaction between parasites and vertebrate
host cells. They showed that after 72 h with 200 μM
CdTeQD, important morphological alterations were induced
in T. cruzi, such as DNA damage, the formation of blisters in
the plasma membrane and mitochondrial swelling. However,
parasites incubated with CdTe QDs at 2 μM continued to
proliferate after seven days. In conclusion, a low concentra-
tion of CdTe QDs (2 μM) is optimal for bioimaging, while a
higher concentration (200 μMCdTe) can be toxic to cells due
to the resulting morphological changes.
Nanoemulsions
Nanoemulsions (NEs) are emulsions of nanometric particles
ranging between 10 and 600 nm,82 consisting of a mixture
of insoluble liquids in two phases in which vesicles in the
dispersed phase are surrounded by a continuous phase. This
nanomaterial is ideal for improving the solubility of hydro-
phobic drugs. Different types of surfactants are used to
stabilize the emulsion in order to prevent the dispersed
phase from fusing in a macroscopic phase.83 The advantage
of these nanoemulsions is their mutual compatibility - solu-
bility in aqueous media and the ability to protect drugs from
hydrolysis and enzymatic degradation.84,85
Oliveira et al86 used ursolic acid, a molecule with try-
panocidal action, in nanoemulsions which were stable for
90 days, 57.3 nm in size and had a polydispersity index of
0.24. The dissolution profile in alkaline medium showed a
release of 75% ursolic acid after 5 mins. Biological studies
showed that the developed formulation was non-toxic in
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LLC-MK2 fibroblast cells (monkey kidney) and possessed
anti-amastigote activity in the CL Brener strain, with a
Selective Index (SI) of 21.66 μM and an IC50 of 18 μM.
Vermelho et al87 synthesized NEs with sulfonamides
and clove oil (Eugenia caryophyllus). Previous studies
have shown that sulfonamide carbonic anhydrase inhibi-
tors targeting the α-class enzyme from T. cruzi have high
trypanocidal activity at 4 µM. Growth inhibitions of 57%
and 43.51% were observed in DM28c and Y strain epi-
mastigotes, respectively. In addition, cellular toxicity
against RAW 267.4 macrophages had an SI value ranging
from 1 to 3, compared to the reference drug benznidazole
(SI =5–5.8). These effects are probably due to greater
enzyme inhibitor penetration through nanoemulsion for-
mulation that had average sizes of 35–100 nm and a PDI
of less than 0.3, indicating that the size distribution is
homogeneous and monomodal.
A nanosystem was recently developed to release benz-
nidazole from oil nanoemulsions and showed efficacy
against Trypanosoma cruzi parasites (Y strain).88 This
nanostructure was established with a transition from lami-
nar liquid crystal to nanoemulsions using cosolvents. They
showed a diameter of 241.60±17.10 nm, PdI of 0.23 and a
zeta potential of −71.40±4.9 mV, and these characteristics
favored the improved aqueous solubility of the drug and
slow its release rate. In addition, the in vitro cellular
biocompatibility of the formulations was evaluated in
Vero and SiHa cell lines, showing slight cytotoxicity up
to 200 μg/mL for both cells, whereas IC50 on epimasti-
gotes was ~0.30 μg/mL and 0.53 for trypomastigotes. The
obtained results indicating these nanoemulsions are poten-
tial colloidal drug delivery system candidates.
Micelles
Micelles are composed of amphiphilic polymers that self-
assemble into nanomaterial ranging from 20–200 nm in size,89
which are generally in the form of spherical vesicles. They
contain a hydrophobic core into which hydrophobic sub-
stances, such as pharmacological compounds, can be intro-
duced for release in different parts of the body. These
nanomaterials provide greater solubility and stability of hydro-
phobic drugs,90 especially in vivo when compared with the
free drug. Furthermore, they are able to i) improve cellular
uptake of drug-loaded micelles, and ii) provide an alternative
form of internalization (endosomes).91–94
Another strategy to release poly-aggregate amphotericin
B (AmB) was developed by Rolon et al95 which involved
two types of formulation: 1) AmB polyamide encapsulated
in albumin microspheres (AmB-AME), and 2) dimeric
AmB-sodium deoxycholate micelles (AmB-NaDC). The
dimeric AmB-NaDC exhibited a promising selectivity
index (SI =3164) for T. cruzi amastigotes, which was
much higher than those obtained for the licensed drugs -
benznidazole and nifurtimox. In vivo experiments adminis-
tered AmB-NaDC orally at 10–15 mg/kg/day for 10 days in
BALB/c mice infected with the T. cruzi Y strain, with a
75% reduction of parasitemia and prolonged survival
observed in the acute phase. Similarly, AmB-AME at
5 mg/kg increased survival and reduced parasitemia by
3.6 times after 7 days of infection in the acute phase,
compared with the AmB-NaDC form. However, toxicity
associated with parenteral administration was observed
with AmB-AME that can be attributed to cardiomyopathy,57
which renders them more susceptible to the side effects
associated with AmB infusion. This study suggested further
AmB-NaDC pharmacokinetic investigations for the clinical
development of a cost-effective and orally bioavailable
AmB treatment for Chagas disease.
Nanocarriers for photodynamic
Currently, many studies are being carried out with photo-
dynamic therapy in several areas of medicine such as
cancer, skin diseases, macular degeneration, psoriasis,
atherosclerosis, myopia and others. In addition, they can
be applied against microorganisms, such as fungi, bacteria,
viruses and protozoa.96–98 Photodynamic inactivation was
tested in vitro on trypomastigotes (Y strain) using the
water-soluble photosensitizer hypericin, formulated with
ethanol/water, loaded in different systems of aqueous
nanocarriers, such as polymeric micelles Poloxamers
(Pluronic™ surfactants) and liposomal phospholipid vesi-
cles 2-dipalmitoyl-sn-glycero-3-phosphocholine.99 These
systems had activity to eradicate the trypomastigote
forms in the dark, however with a stronger activity under
light. For instance, the pluronic micelles showed EC50
around 6–8 μmol/L tested in the dark and 0.31–
0.36 μmol/L under light whereas using the lipid vesicles
the values were 10.84±0.47 μmol/L in the dark and ~5 fold
less (2.22±0.52 μmol/L) under light. Although the results
are promising, further investigation is needed to assess
whether these systems have photo-efficacy in vivo.
Nanodiagnostics
Some nanodiagnostic tools are based on nanomaterials
such as liposomes, nanopores, nanowires and metallic
nanoparticles, which are combined with conventional
Dovepress Quijia Quezada et al
International Journal of Nanomedicine 2019:14 submit your manuscript | www.dovepress.com
DovePress
6417
methods such as fluorescence, potentiometry, and voltam-
metry. It incorporates biological recognition elements or
biomimetics, including nucleic acids, enzymes, antibodies,
receptors, tissue, cells, inflammatory proteins from macro-
phages, aptamers and peptides.100,101 The interaction
between the compound or microorganism of interest and
the recognition element produces a variation in one or
more physicochemical properties (such as: pH, electron
transfer, heat, potential, mass, optical properties, etc.)
that are detected by a transducer. The resulting electronic
signal indicates the presence of an analyte of interest and
its concentration in the sample. Therefore, nanobiosensors
are revolutionizing the in vitro diagnosis of diseases and
have important implications for human health.
Biosensors based on electrically active field effect
transistors (FETs) offer direct, rapid and highly sensitive
detection capabilities without labeling several biomole-
cules of specific interest. Nanowires (NW) are more
efficient bioelectrochemical transducers, compared to
their thin film analogs, so they are used as efficient
detection biosensors.102
An integrated microfluidic system coupled to screen-
printed carbon electrode (SPCE) has been developed to
quantify specific IgG antibodies present in serum samples
from Chagas disease patients.103 The principle is based on
an SPCE coupled to a microfluidic device modified by the
electrodeposition of gold nanoparticles (AuNP) functiona-
lized with T. cruzi proteins from epimastigote membranes.
A microfluidic immunosensor was used to detect specific
anti-T. cruzi IgG antibodies that reacted immunologically
with the immobilized T. cruzi antigen. The calculated
detection limit was 3.065 ng/mL and the intra-assay and
inter-assay variation coefficients were lower than 6.95%.
These values demonstrated this immunosensor could be
used as a serological method for the diagnosis of conge-
nital Chagas disease in addition to donor blood screening
and monitoring antibody reduction during the treatment of
chagasic patients.103
Early and non-invasive diagnosis for congenital
Chagas disease concentrates, preserves and detects T.
cruzi antigens from the patient’s urine (Figure 3).104 The
Chagas urine nanoparticle assay (Chunap) was effective
for a single urine sample from a one-month-old baby with
more than 90% sensitivity and more than 95% specificity.
Nanoparticles were functionalized with polyunsaturated
N-isopropylacrylamide and trypan blue, which can capture
and concentrate T. cruzi analytes from different chemical
structures, including proteins (H49 and 1F8), glycopro-
teins (TESA) and lipophosphoglycans.
Surface functionalization and covalent immobilization
of biomarkers, using biocompatible ethanolamine and
polyethylene glycol derivatives, substantially increases
the sensitivity and molecular selectivity of biosensors
based on field effect transistors (nano-FET).105 The
authors achieved significantly improved binding specifi-
city, biomarker density and capture efficiency of target
biomolecules for DNA as well as pathogen proteins. The
developed devices provided ultra-high sensitivity capable
of detecting approximately ~1 fM for specific DNA
sequences and 6 fM for a protein marker of Chagas disease
(IBMP8-1), measured by the net change in electrical resis-
tance of the device. The developed InP nanowire biosensor
provides a qualified tool for the detection of the chronic
stage, leading to better diagnosis and spreading control.
Currently, there are few conventional tests for Chagas
disease diagnosis, causing a limitation in parasite detection
in acute and chronic phases. Providing detection of the
different stages of infection using nanobiosensors would
Figure 3 Chunap assay for the early diagnosis of congenital Chagas disease. Chunap (Chagas urine nanoparticle assay) is to perform an early and non-invasive diagnosis for
congenital Chagas disease, by concentrating, preserving and detecting antigens secreted/excreted by trypomastigote forms (TESA) from urine by Western Blot.
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lead to better diagnosis and spreading control. Another
advantage within the limit of detection based on nanoma-
terials is the use of a wide range of biological fluids such
as blood, saliva or urine.106 Therefore, they could improve
the monitoring of patients’ treatment in terms of speed,
small sample volume, ease of use, real-time detection and
low cost compared to current conventional tests.107 That
said, more research efforts are still needed to develop these
types of nanodiagnostics.
Nanovaccine
Studies have shown the importance of CD4+ and CD8+ T
cell responses against T. cruzi infection.108–110 Attention is
directed toward antigens that elicit cell-mediated immune
responses and would result in immune recognition of host
cells infected with parasites.111,112 A favourable immune
response would have the ability to trigger the production
of the cytokine associated with IFN-γ induced Th1
response by CD8+ T cells. Depletion of CD8+ T cells in
mice results in uncontrolled parasitemia and high
mortality.113,114 A therapeutic vaccine for Chagas disease
has potential advantages, such as reduction in side effects
and the potential to be used as a replacement for current
therapies or in parallel with low doses of chemotherapy.115
Adjuvants
Adjuvants are used to increase the immune response
against vaccine antigens, achieve homogeneous responses
in vaccinated individuals, decrease the amount of antigen
used, reduce the number of vaccine doses and direct a
beneficial response profile.116 This is achieved using mole-
cules that stimulate pattern recognition receptors (PRRs),
using strategies that improve the uptake and presentation
of antigens by dendritic cells, promoting the antigen trans-
port by lymph node drainage or by deposit formations.117
A study conducted by Bertona et al118 evaluated ISPA
immunostimulatory nanoparticles and developed an adju-
vant based on cage-like particle composed of Q. sapo-
naria, phospholipids (PL), cholesterol (CHOL) and
hydrophobic antigens associated in a single nanostructure.
The size of the nanomaterial was 42.1 nm and the zeta
potential was −1.96 mV. The authors compared it to dif-
ferent adjuvants such as Freund Adjuvant (FA), aluminum
hydroxide (AH), Montanide TM ISA 206 (I206) and the
commercial form ISCOMATRIX™ (IMX) aiming to
determine the level, kinetics and humoral response profile
against the parasite (Tulahuen strain) used female BALB/c
mice. Unlike the individual effect of these adjuvants,
combined ISPA particles improved the immune response
against specific antigens, reduced the number of doses,
provided a homogenized response among individuals and
a balanced Th1/Th2 response. Moreover, mice immunized
with ISPA and trans-sialidase (TS) generated a complete
protective immune response when challenged with T. cruzi
parasites.
Proteoliposomes
The reconstitution of membrane proteins in liposomes has
proved to be a useful tool for preparing antigenic components
to induce immunity in experimental models.119,120 Regarding
cellular immune responses, Mesa et al121 showed that very
small proteoliposomes can act as effective adjuvants for Th1
polarization and dendritic cell activation.
In this context, proteoliposomes for T. cruzi transport
proteins were prepared from sonicated trypomastigotes
and amastigotes (Y strain),122 and mixed with sodium
dodecyl sulfate (SDS) to achieve maximum solubilization
of parasite membranes, without destroying protein antige-
nicity. The resulting proteoliposomes, with a mean dia-
meter of 199 nm, were used to immunize BALB/c mice,
which were further infected with trypomastigotes.
Intraperitoneal macrophages collected one week after the
in vivo infection, were infected in vitro and showed a
significant decrease of intracellular parasites 72 h later,
in comparison with the controls. Despite the generated
antibodies, macrophage activation and delayed animal
death, no difference was noted with regards to survival
rate between the groups on day 30 after infection. In
conclusion, although these proteoliposomes do not protect
mice from challenge with a virulent strain of T. cruzi, the
improvement of these membrane mimic systems as immu-
nogenic vehicles for parasite molecules could eventually
contribute to the development of an effective vaccine.
PLGA nanoparticles
Considered a promising antigen target,123 Tc24 is a cal-
cium-acyl exchange protein located in the parasite flagellar
pocket which is expressed at all stages of T. cruzi
development.124 Prophylactic immunization with Tc24 is
protective against T. cruzi infection125,126 and induces high
levels of antigen-specific IFN-γ CD8+ cells, protecting
against both parasitemia and cardiac pathology. In
humans, recombinant Tc24 has been used as an antigen
for Chagas disease serodiagnosis and as a tool to monitor
treatment success.127,128 A PLGA nanoparticle-based
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vaccine containing oligodeoxynucleotides with the CpG
motif (CpG ODN) as an immunomodulatory adjuvant
has been designed which acts as a TLR-9 agonist. CpG
ODNs have been described as potent immune response
stimulators of Th1-mediated CD8+ T cells.129,130
PLGA nanoparticles produced with CpG ODN and
recombinant Tc24 protein provide a deposit effect similar
to Aluminum hydroxide Gel (Alhydrogel®) in immunized
mice, allowing the prolonged release of Tc24 antigen. In
addition, the vaccine produced a skewed Th1 immune
response, demonstrating a significant increase in antigenic
splenocytes producing specific IFN-γ, IgG2a titers, and
CD8+ T cell proliferative capacity. This study provided
important evidence of the principle that PLGA nanoparti-
cles can be used as a delivery system to improve both the
immunogenicity and efficacy of a protein-based vaccine
for Chagas disease.131
In summary, the desirable features of vaccine against T.
cruzi infection are the ability to decrease the parasitic
burden, inflammation, and damage of heart tissue or
increase host survival.132–135 It has been shown that nanos-
tructural systems or immunogenic vehicles are better than
conventional therapies, showing a system of directed-
administration, such as the use of specific antibodies or
ligands to transport drugs directly to their targets. Thus, a
successful nanovaccine should induce a strong cellular
immune response, with the activation of CD8+ T cells to
effectively control the parasites.108–110
Conclusion
Nowadays, there are not enough data to predict whether
the nanoparticles will offer improved effective antichaga-
sic treatments. Preclinical data analyzed herein has not yet
clearly shown the successive elimination of intracellular
parasites such as in chronic asymptomatic cases, or non-
rodent immunized animal models.30,36,41,42,50,59,95,136,137
Moreover, the only nanoparticulate system approved for
clinical trials is liposomal amphotericin B (LAMB), how-
ever, it has been shown to have little anti-T. cruzi
activity.138,139
Trypanocidal activity on different forms of T. cruzi
would be essential for an excellent nanoparticulate system.
However, neither amastigotes nor trypomastigotes are as
effective in uptaking nanoparticles as epimastigotes.140
Ideally, nanoparticles must have a size smaller than
250 nm and the surface charges must depend on the
established goal. For the acute phase of the disease, a
neutral or slightly negative nanoparticle surface charge is
desired for intravenous administration since nanoparticles
reduce the adsorption of serum proteins, resulting in
longer half-lives in the circulation141 and therefore, pro-
moting a controlled drug release in the body. For indeter-
minate and chronic phases, nanoparticles with a positive
surface charge would be desirable to reach infection sites
since they have a higher rate of non-specific uptake in
most cells.142 In addition, nanomaterial must function at
different pH’s, allowing massive and selective targeting to
infected cells, and a more drastic reduction in parasitemia
levels.137 Finally, this review provided an overview of
recent advances in development and design of new strate-
gies to synthesize nanoparticulated systems for treatment
against Chagas disease.
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